A Phase 3 interventional study of Posaconazole and Fluconazole in Leukopenia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A randomized, open label parallel controlled, multicenter study to evaluate safety and efficacy of Posaconazole oral suspension vs Fluconazole (capsule) in high-risk leukopenic patients for prevention of invasive fungal infection
30 studies on the registry are indexed under Leukopenia; 7 are open to participants now.
This study's enrollment of 252 is above the median of 57 across 18 interventional studies indexed under Leukopenia.
Browse Leukopenia studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Persistent neutropenia ( [ANC] \< 500/mm\^3 [0.5x10\^9/L])or probable neutropenia in 3-5 days is anticipated. Neutropenia >= 7 days caused by the following reasons
Exclusion Criteria:
Participants who have taken the following drugs:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Posaconazole oral suspension 200 mg three times a day (TID)
Drug: Posaconazole
Fluconazole 400 mg once daily (QD)
Drug: Fluconazole
40 mg/mL; 200 mg (5 mL) TID Treatment was continued with each cycle of chemotherapy until: * The onset of a proven or probable diagnosis of invasive fungal infection (IFI) * 3 chemotherapy cycles or * Total treatment duration up to 12 weeks (84 days)
Also known as: Noxafil, SCH 056592
50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules); 400 mg QD Treatment was continued with each cycle of chemotherapy until: * The onset of a proven or probable diagnosis of invasive fungal infection (IFI) * 3 chemotherapy cycles or * Total treatment duration up to 12 weeks (84 days)
Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period
Number of participants developing a proven or probable IFI from randomization to the last dosage date (up to 12 weeks \[84 days\]) plus 7 days. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.
Time frame: Up to 12 Weeks (84 days) plus 7 days
Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization
Number of participants who developed a proven or probable IFI from randomization date to Day 100 of follow-up visit. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.
Time frame: From randomization date to Day 100
Time From Randomization to the First Onset of Proven or Probable IFI
The time measured in days to the first occurrence of proven/probable IFI diagnosis in the entire FAS population from randomization to Day 100 of follow-up visit. Participants may not have accepted immediate antifungal treatment and later received antifungal treatment based upon further investigator review of the participant's IFI condition. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, positive blood/biopsy cultures with corresponding clinical signs and symptoms.
Time frame: From randomization date to Day 100
Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy
The time measured in days from randomization to the administration of the first concomitant systemic anti-fungal therapy in the entire FAS population. Not all participants who accepted systemic anti-fungal therapy may have had a IFI clinical diagnosis. IFI diagnosis criteria for antifungal therapy administration may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.
Time frame: Up to 12 weeks (84 days)
Number of Participants With Clinical Failure During Treatment
Clinical failure was defined as follows: * Presence of a proven or probable IFI * Systemic antifungal treatment (IV) for 4 consecutive days or more than 10 days total * Discontinuation due to adverse event (AE) possibly or probably related to study drug * Lost-to-follow-up or discontinuation from the study for any reason with loss to follow-up during the Treatment Phase
Time frame: Up to 12 weeks (84 days)
Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization
Death from any cause.
Time frame: Randomization date to Day 100
Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization
Exact Causes of Death and Their Relationship to IFI Episode Were As Follows: * Unlikely related: participant completed treatment and cause of death was due to primary disease or complication * Possibly related: IFI undergoing treatment without stabilization, or with failure to have a complete remission, where cause of death might have been due to IFI, including progression or relapse of primary disease * Probably related: autopsy or clinical signs suggested that progression of IFI was the probable cause of death
Time frame: From randomization date to Day 100
| Milestone | Posaconazole | Fluconazole |
|---|---|---|
| Started | 129 | 123 |
| Completed | 90 | 90 |
| Not completed | 39 | 33 |
| Withdrew: Aes and saes including death | 7 | 11 |
| Withdrew: Withdrawal by subject | 18 | 12 |
| Withdrew: Did not take study drug | 3 | 0 |
| Withdrew: Without primary efficacy endpoint data | 7 | 4 |
| Withdrew: Investigator decision | 2 | 1 |
| Withdrew: Poor compliance | 2 | 5 |
Number of participants developing a proven or probable IFI from randomization to the last dosage date (up to 12 weeks \[84 days\]) plus 7 days. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.
| participants | Posaconazole | Fluconazole |
|---|---|---|
| Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period | 4 | 11 |
Number of participants who developed a proven or probable IFI from randomization date to Day 100 of follow-up visit. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.
| participants | Posaconazole | Fluconazole |
|---|---|---|
| Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization | 5 | 16 |
The time measured in days to the first occurrence of proven/probable IFI diagnosis in the entire FAS population from randomization to Day 100 of follow-up visit. Participants may not have accepted immediate antifungal treatment and later received antifungal treatment based upon further investigator review of the participant's IFI condition. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, positive blood/biopsy cultures with corresponding clinical signs and symptoms.
| Days | Posaconazole | Fluconazole |
|---|---|---|
| Time From Randomization to the First Onset of Proven or Probable IFI | 8 | 2 |
The time measured in days from randomization to the administration of the first concomitant systemic anti-fungal therapy in the entire FAS population. Not all participants who accepted systemic anti-fungal therapy may have had a IFI clinical diagnosis. IFI diagnosis criteria for antifungal therapy administration may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.
| Days | Posaconazole | Fluconazole |
|---|---|---|
| Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy | 4 | 1 |
Clinical failure was defined as follows: * Presence of a proven or probable IFI * Systemic antifungal treatment (IV) for 4 consecutive days or more than 10 days total * Discontinuation due to adverse event (AE) possibly or probably related to study drug * Lost-to-follow-up or discontinuation from the study for any reason with loss to follow-up during the Treatment Phase
| participants | Posaconazole | Fluconazole |
|---|---|---|
| Number of Participants With Clinical Failure During Treatment | 37 | 51 |
Death from any cause.
| participants | Posaconazole | Fluconazole |
|---|---|---|
| Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization | 3 | 8 |
Exact Causes of Death and Their Relationship to IFI Episode Were As Follows: * Unlikely related: participant completed treatment and cause of death was due to primary disease or complication * Possibly related: IFI undergoing treatment without stabilization, or with failure to have a complete remission, where cause of death might have been due to IFI, including progression or relapse of primary disease * Probably related: autopsy or clinical signs suggested that progression of IFI was the probable cause of death
| participants | Posaconazole | Fluconazole |
|---|---|---|
| Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization | 0 | 0 |
Collected over From screening to the last dosage date plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Posaconazole | — | 7/124 (5.6%) | 82/124 (66.1%) |
| Fluconazole | — | 10/121 (8.3%) | 81/121 (66.9%) |
| Event | Posaconazole | Fluconazole |
|---|---|---|
| DeathGeneral disorders | 1/124 | 2/121 |
| Cerebral haemorrhageVascular disorders | 2/124 | 1/121 |
| Bone marrow depressionBlood and lymphatic system disorders | 1/124 | 1/121 |
| Intestinal haemorrhageGastrointestinal disorders | 0/124 | 1/121 |
| SepsisInfections and infestations | 1/124 | 1/121 |
| Septic shockInfections and infestations | 0/124 | 1/121 |
| Cerebellar haemorrhageNervous system disorders | 0/124 | 1/121 |
| Consciousness disturbanceNervous system disorders | 0/124 | 1/121 |
| Respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/124 | 1/121 |
| OedemaGeneral disorders | 1/124 | 0/121 |
| Event | Posaconazole | Fluconazole |
|---|---|---|
| PyrexiaGeneral disorders | 39/124 | 39/121 |
| Hepatic function abnormalInvestigations | 25/124 | 21/121 |
| ENT disorderRespiratory, thoracic and mediastinal disorders | 23/124 | 20/121 |
| Electrolyte imbalanceMetabolism and nutrition disorders | 20/124 | 15/121 |
| RashSkin and subcutaneous tissue disorders | 19/124 | 19/121 |
| GingivitisGastrointestinal disorders | 19/124 | 18/121 |
| DiarrhoeaGastrointestinal disorders | 15/124 | 17/121 |
| Respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 17/124 | 16/121 |
| NauseaGastrointestinal disorders | 16/124 | 15/121 |
| Anal disorderGastrointestinal disorders | 11/124 | 14/121 |
| Age, Continuous(participants) | Posaconazole | Fluconazole | Total |
|---|---|---|---|
| Mean | 39.3 ± 13.01 | 40.6 ± 12.50 | 40.4 ± 12.73 |
| Sex: Female, Male(Participants) | Posaconazole | Fluconazole | Total |
|---|---|---|---|
| Female | 62 | 65 | 127 |
| Male | 55 | 52 | 107 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Nov 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 4 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Posaconazole · Fluconazole